View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20250311697254/en/" rel="nofollow">https://www.businesswire.com/news/home/20250311697254/en/</a>
Already have an account? <a class="fw-bold color-title-3 st-link" data-bs-toggle="modal" data-bs-target="#login-modal">Login</a>
By Robin Bravender |  03/19/2025 01:36 PM EDT 
who served as then-Vice President Mike Pence’s communications director
is now among Interior Secretary Doug Burgum’s top staffers
A former top staffer for then-Vice President Mike Pence is serving as a senior aide to Interior Secretary Doug Burgum
although his formal title and role have not been announced publicly
who served as Pence’s communications director from 2017 until 2019
has landed in Burgum’s inner circle at the department
according to two people familiar with Interior’s staffing who were granted anonymity to discuss personnel
Interior has been secretive about the identities of its political appointees during Trump’s second term, and the secretary’s office has already witnessed turnover. Burgum’s former chief of staff, Wynn Radford, <a href="https://subscriber.politicopro.com/article/eenews/2025/03/03/interior-chief-of-staff-replaced-by-longtime-burgum-ally-00208799" target="_blank">was replaced</a> by acting chief of staff and longtime Burgum ally JoDee Hanson just a month into the secretary’s tenure
Agen’s exact role and title remain unclear
although one of the people familiar with Interior’s staffing said Agen is close to the secretary and is viewed as one of his key advisers
 Request a FREE trial to receive unlimited access to 
(Togo First) - A delegation from France’s Agen conurbation visited Lomé last week to finalize a cooperation deal with Togo’s Golfe 1 commune
Agen president Jean Dionis led the team to sign a memorandum focused on operational partnerships and territorial innovation
The agreement includes concrete actions: Agen will supply Golfe 1 with two dump trucks and 200 refuse bins to improve waste collection
Golfe 1 Mayor Koamy Gomado called the deal a “win-win” for both parties
The collaboration aims to foster business growth by connecting economic players in both regions
reflecting a shift toward decentralized cooperation as a tool for internationalizing territories
STARTING A BUSINESS  (<a href="/en/reforms-relative-to-starting-a-business">more info</a>)
under the Starting a Business index of the 2020 Doing Business ranking
Togo sustains its reformative dynamics with more reforms…
ENFORCING CONTRACTS (<a href="/en/reforms-relative-to-enforcing-contracts">more info</a>) 
Compared to some years ago when it was one of the lowest rankers under the Doing Business’ Enforcing Contracts indicator
leveraging many efforts to improve its business climate
was able to jump significantly on the index in the recent years..
CONTRACT EXECUTION (<a href="/en/reforms-relative-to-contract-execution">more info</a>)
Creation of special chambers of commerce for small debts &nbsp;• Creation of chambers of commerce at the Court of Appeal &nbsp;• Civil and commercial cases now handled by distinct clerks &nbsp;• Establishment of commercial courts in Lomé and Kara &nbsp;• Lawyers and bailiffs now have access to the FORSETI COMMERCIAL platform&nbsp;• A maximum period of 100 days was fixed to settle a commercial dispute 
TRADING ACROSS BORDERS  (<a href="/en/reforms-relative-to-trading-across-borders">more info</a>)
In comparison to previous years,Togo has significantly improved its ranking under the“Trading across borders” indicator by adopting multiple reforms that focus mainly on the digitization and reduction in delays
for import and export procedures related to import and export
Togo has significantly improved its ranking on the “Trading across borders” index by adopting multiple reforms that focus mainly on the digitalization and reduction in delays
CONSTRUCTION PERMIT  (<a href="/en/reforms-relative-to-construction-permits">more info</a>)
After moving from the 133rd to 127th place under the 2020 Doing Business’ construction permit index
Togo intends to reiterate this feat in the coming edition of the global ranking
it has introduced this year multiple reforms
GETTING ELECTRICITY  (<a href="/en/reforms-relative-to-getting-electricity">more info</a>)
Togo’s ranking under the Doing Business’ Getting electricity and water indicator has increased consistently
Owing this performance to multiple reforms aimed at making it easier for businesses to access power and water
Lomé plans to introduce even more reforms this year to keep up its improvements
REGISTERING A PROPERTY &nbsp;(<a href="/en/reforms-relative-to-property-registration">more info</a>)
Out of all the 'Doing Business’ indicators
Property Registration is where Togo has improved the most since 2018
after spending years in the lowest part of this ranking
the country now seeks to beat Rwanda which is the best performer on this index in Africa
with the latest batch implemented this year
PUBLIC PROCUREMENT&nbsp;(<a href="/en/reforms-relative-public-procurement">more info</a>)
Togo’s public procurement framework is constantly being modernized
Several reforms have been implemented to improve the sector much to the benefit of the private sector
which is the focus of the National Development Plan
PAYING TAXES AND DUTIES (<a href="/en/reforms-relative-paying-taxes-and-duties">more info</a>)
Togo introduced some important reforms related to the payment of tax and duties
From the replacement of some taxes to the cancellation of others through exemptions
the country has only one objective: offer the most attractive tax framework to investors and economic operators
<a href="https://play.google.com/store/apps/details?id=com.goodbarber.togofirst" target="_blank" rel="noopener"></a>
To contact us: c o n t a c t [@] t o g o f i r s t 
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20250428583362/en/" rel="nofollow">https://www.businesswire.com/news/home/20250428583362/en/</a>
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20250423929145/en/" rel="nofollow">https://www.businesswire.com/news/home/20250423929145/en/</a>
The Motley Fool is a financial services company dedicated to making the world smarter
The Motley Fool reaches millions of people every month through our premium investing solutions
free guidance and market analysis on Fool.com
AGEN earnings call for the period ending December 31
Agenus (<a class="ticker-symbol" href="/quote/nasdaq/agen/">AGEN</a> -0.64%)Q4 2024 Earnings CallMar 11
and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call
all participants are in a listen-only mode
A question-and-answer session will follow the formal remarks
I will now turn the call over to Zack Armen
and welcome to Agenus' fourth-quarter and year-end 2024 financial results and corporate update call
we issued a press release detailing our financial results and key corporate developments
A copy of the press release is available on our website at www
I'd like to remind everyone that today's discussion will include forward-looking statements
These statements are subject to risks and uncertainties which may cause actual results to differ materially from expectations
Please refer to our SEC filings for further detail
chief commercial officer; Christine Klaskin
VP finance and principal financial and accounting officer
Armen -- Chairman and Chief Executive Officer
A very good morning once again from a delightful day in Lexington
pleased to report that we delivered on our commitment to significantly reduce Agenus' operational burn
we had reduced our annualized burn rate to the level that we had guided everyone
we are executing on our next phase of strategic cost reductions with an annualized burn to approximate 50 million by the middle of this year
and we're very much on track for that number
Our objective is to direct every available resource toward what truly matters to our stakeholders and patients
to make sure that our groundbreaking potential or BOT/BAL is realized
and patients have access to it as soon as possible
BOT/BAL continues to demonstrate unprecedented clinical activity
Recently we presented at major oncology forums such as AACR Immuno Oncology for the first year that AACR organized the immuno oncology division of its annual conference
ASCO-GI in January; SITC in the fall; ESMO and ESMO-GI
And we detailed the most influential peer-reviewed journals including Nature Medicine; JCO
Journal of Clinical Oncology; and Cancer Discovery
All of these were accomplished in the last 12 months or less
We are witnessing transformative clinical outcomes in colorectal cancer and other tumors that had been historically unresponsive to immunotherapy
This is based on the opinion of some of the most prestigious experts in the field
BOT/BAL has demonstrated durable -- and I want to underline durable -- responses and prolonged survival in refractory microsatellite stable colorectal cancer
We've seen encouraging activity with the addition of BOT/BAL to FOLFOX
but in terms of both efficacy and tolerability
We have also either seen complete or near-complete pathological responses
in neoadjuvant MSS as well as MSI-high CRC
Even though the trade likes to break these into two categories
our agents are active in both categories of colorectal cancer
This has transformative potential to enable chemo radiation and
surgery-free options for patients because in some cases like rectal cancer
particularly the fact that CRC and rectal cancer are now being seen more and more frequently in younger patients
these outcomes aren't just our internal assessment
Leading global oncology centers and experts are independently conducting investigator-sponsored trials
all we need to do is just provide product for them
This independent validation by some of the most respected oncologists and oncology centers
who are pivotal in securing approval in our breakthrough therapies
significantly amplify our confidence in BOT/BAL and its potential for patients
are expected to rapidly enroll in potentially organ-sparing trials with BOT/BAL
we have a new trial that's gotten underway this week with inquiries that had come in from patients ahead of the official opening of the trial
with strategically continued monitoring and monetizing
our high-value biologics manufacturing facility in Emeryville and Berkeley
our land in Vacaville to fortify our balance sheet
we're engaged in also late-stage partnership discussions to secure funding for BOT/BAL and BOT/BAL development and registration with an emphasis on neoadjuvant treatment of early stage -- well
but intermediate stage colon and rectal cancers -- where these are clear opportunities for BOT/BAL to provide significant benefit to patients
I'll turn it over to Christine for a quick review of our financials
Finance and Principal Financial Accounting Officer
We ended the year 2024 with a consolidated cash balance of $40.4 million
This compares to a balance of $76.1 million at December 31
Cash used in operations for the year ended December 31
This is reduced from $224 million for the prior year
we recognized revenue of $103.5 million and incurred a net loss of $232.3 million or $10.59 per share
we recognized revenue of $26.8 million and incurred a net loss of $46.8 million or $2.04 per share
Our revenue primarily consists of a non-cash royalty revenue
while we recognize that our financial position is not reflective of the high potential on the promise of our product and it's a bit tighter than ideal
we are taking decisive actions to continue to -- and we will continue to take very decisive actions to bolster our cash position as well as to contain costs
we're very heartened by the fact that we've had significant external validation through numerous selected high-quality centers that are doing trials
and robust clinical activity that we have seen in BO/BAL
position us to advance our lead programs in 2025 and beyond
We remain committed and strategically aligned to deliver groundbreaking treatments for patients
This is very important because having treated now well over a thousand patients across nine different cancers with a heavy concentration on colon cancer and seeing the benefit to patients
it's very heartening that we have kept our eye on developing BOT/BAL as a high priority for us
and I think we welcome questions that you may have
[Operator instructions] We kindly ask that you please limit your questions to one and one follow-up
Our first question will come from the line of Emily Bodnar with H.C
if you can kind of help frame the cost reductions for us
particularly which programs are being impacted the most
particularly on the R&amp;D side and especially into mid 2025 as you're guiding to additional cost cuts
if you can kind of walk us through expected catalysts for 2025 and any new data updates or regulatory updates that we should be looking out for
the cost reductions really center around headcount reductions that are nonessential
meaning that given our priority being BOT/BAL development and registration
we have defined exactly which experts we need internally and externally
and we have significantly cut down on external advisors
We have limited external advisors to those that will benefit us the most in terms of advancing BOT/BAL to a line of registration and most of the registration work that we were undertaking under accelerated approval is already completed
we will utilize a lot of the work that has been completed to seek potentially registration
We have simply shelved them for the time being
and we've done it in a way that we can reignite them because
we got a significant number of products back from our partners after they have spent in excess of $800 million collectively on those products
not because of any product performance issues
but strictly because of the fact that IO for the time being is out of factory
not because we believe our products are implicated in it being out of factory
and that doesn't mean that it will remain cold three
we have put them on hold with an intent to reignite them quickly
In terms of catalysts for 2025 on the regulatory updates
[Operator instructions] And our next question comes from the line of Mayank Mamtani with B
Maybe just a similar question as asked before on the process of monetization of noncore assets
if you could comment how further along you are and what sort of economics you could derive from that
the first stage of monetization of our West Coast assets
came in the form of a mortgage that we obtained back in November
it was almost impossible for us to obtain a mortgage
But we got a $20 million mortgage at a record time in approximately two weeks
for those of you who have been to our Emeryville facility
state-of-the-art manufacturing facility that is synchronized
given the fact that there has been significant shift in U.S
with parties for the potential consummation of monetization of our West Coast manufacturing and real estate assets
And then are you able to share your latest and greatest thoughts on what registrational program could look like
ASCO-GI data recently showed a number of different directions you could go in
Any thoughts in each of those buckets that could be helpful for folks to understand the path to market here
we have amassed an enormous amount of data in the late-stage setting
There's no ambiguity about our ability to rescue patients with MSS CRC who have exhausted no other option
even though we haven't done a randomized trial in late stage yet
There is no ambiguity about the fact that these patients are living much longer
orders of magnitude longer than patients who have had standard of care
we have more than doubled the response rates in these patients
And we have an extension of their lifespan that is based on our current data
essentially double what you would see with standard of care
is of great interest to the experts in the field and patients
we have patients who are going on disease-free now pushing three years
that's one area where with more mature data
we will make an effort to get the interest of regulators around the world
the data from the neoadjuvant setting is unambiguous because when I say unambiguous
These patients are treated only with BOT/BAL
And what we're seeing is complete pathological responses in more than half patients
by the way -- there was some concern that the data was from a single center
the data corroborates the Cornell data in 11 centers from Europe and in four times the patients
Because of the black and white nature of the outcomes in MSS CRC and MSI-high
we believe that there is a clear path for potential approval
particularly in a setting that will be organ-sparing
And we believe that if we can show that our products are organ-sparing
that will be a significant benefit to patients
In the refractory setting now between our Phase 1 and our Phase 2 trial
we have approximately 350 patients whose data is maturing
And we look forward to really watching this durability of response and treatment-free interval mature and then obviously interact further with regulatory bodies around this data
And then I think what Garo said in the neoadjuvant setting is really remarkable in terms of its ability to change paradigms in both the MS stable and obviously
And rectal cancer is within our sights as a primary first neoadjuvant sort of regulatory approach
Looking for some of these updates in the coming months
who is one of the foremost commercial and beyond commercial experts in CRC
I think the context has been explained certainly in terms of rectal cancer
But I would also point out that both rectal and colon cancer have a significant opportunity because we're looking at not only in rectal cancer potential for chemo sparing
and also sparing debilitating surgery because if we improve the clinical complete response rate
those patients basically will not go on to surgery
And the evidence that we've seen so far with early use of immunotherapy
translates into a prolonged recurrence-free survival
we expect we're going to be able to improve rectal cancer
there is that opportunity to be able to improve the event-free survival
And real question about being able to reduce the amount of chemotherapy that patients are receiving
which has the potential for permanent neuropathy in the long run in these patients who have adjuvants
chemotherapy may end up with permanent neuropathy that could be avoided
And that coupled with the ability to improve on event-free survival and overall survival really makes colon cancer a real significant opportunity as well
just to note that we have just -- there's an IST that was just initiated Memorial Sloan Kettering with Andrea Cercek Phase 2 in rectal cancer that they are very excited about -- patients very excited about
And that will conclude our question-and-answer session
I'll hand the call back over to Garo Armen for any closing remarks
It's always a pleasure to have you and your questions
We're very excited about the prospects of our lead programs
There is more reason to be excited now with the longevity of data than even six months ago
we're grateful to our investigators and patients for participating in these trials to demonstrate the kind of results that we've come up with so far
And we look forward to data maturing and our trials expanding
Garo Armen -- Chairman and Chief Executive Officer
<a href="https://www.fool.com/quote/agen">More AGEN analysis</a>
<a href="https://www.fool.com/earnings-call-transcripts/">All earnings call transcripts</a>
including our Obligatory Capitalized Disclaimers of Liability
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a <a href="https://www.fool.com/legal/fool-disclosure-policy/">disclosure policy</a>
*Average returns of all recommendations since inception
Cost basis and return based on previous market day close
Market data powered by <a class="text-gray-800 hover:text-gray-1100 underline" target="_blank" href="https://xignite.com/">Xignite</a> and <a class="text-gray-800 hover:text-gray-1100 underline" target="_blank" href="https://polygon.io/">Polygon.io</a>
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20250425819815/en/" rel="nofollow">https://www.businesswire.com/news/home/20250425819815/en/</a>
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20241112301834/en/" rel="nofollow">https://www.businesswire.com/news/home/20241112301834/en/</a>
<a href='javascript:history.back()'>&laquo; Back</a>
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20250225022116/en/" rel="nofollow">https://www.businesswire.com/news/home/20250225022116/en/</a>
View source version on businesswire.com: <a rel="nofollow noopener" href="https://www.businesswire.com/news/home/20241205565645/en/" rel="nofollow">https://www.businesswire.com/news/home/20241205565645/en/</a>
In a recent analysis update, B. Riley's financial expert Mayank Mamtani has revised his price target for Agenus (<a href="/stock/AGEN/summary">AGEN</a>, <a target="_blank" title href="/stock/AGEN/financials" class="stock-link">Financial</a>)
reducing it to $8 from a previous target of $11
the analyst maintains a Buy rating on the biotechnology company's shares
The revision follows a review of the company's performance and financial disclosures from its latest earnings report last month
While the adjustment reflects some tempered expectations
the Buy rating indicates continued confidence in Agenus's potential for growth in the biopharmaceutical sector
Based on the consensus recommendation from 5 brokerage firms, Agenus Inc's (<a href="/stock/AGEN/summary">AGEN</a>, <a target="_blank" title href="/stock/AGEN/financials" class="stock-link">Financial</a>) average brokerage recommendation is currently 2.8
For the complete transcript of the earnings call, please refer to the <a href="https://www.gurufocus.com/stock/AGEN/transcripts/2735934" target="_blank" rel="noreferrer noopener">full earnings call transcript</a>
(AGEN) is gearing up to present its cutting-edge advancements in cancer immunotherapy at the prestigious American Association for Cancer Research Annual Meeting in April 2025
This event will spotlight groundbreaking data from the NEOASIS trial and an exploratory Phase 1 study
focusing on the efficacy of botensilimab and balstilimab in combating advanced solid tumors
Consensus from five brokerage firms currently assigns Agenus Inc
(AGEN) an average recommendation score of 2.8
where 1 signifies a Strong Buy and 5 denotes a Sell
Recent reports from France indicate that Agen is finalizing arrangements to bring in Javier Eissmann to bolster their ranks in the Pro D2 league
The Chilean player is set to join as a Medical Joker
stepping in for the injured John Madigan from Ireland
A formal announcement from Agen regarding this transfer is expected to be made in the next few days
Madigan incurred a significant bicep injury during a match against Valence Romans
sidelining him from action with the team until 2025
Agen has turned to Rugby World Cup second-rower Javier Eissmann
a strong and agile 27-year-old lock forward
commenced his professional rugby career with Selknam in Argentina&#39;s Super Liga Americana from 2019 to 2022
joining Sporting Union Agenais in the same position
who stands at an imposing 6 feet 7 inches and weighs 260 pounds
is anticipated to arrive at Agen to fulfill the role of a medical joker
Chile marked its first-ever appearance at the Rugby World Cup in 2023
Eissmann featured prominently in matches against Japan in Toulouse
Eissmann made a notable impact as a replacement player in the match against Samoa in Bordeaux
Eissmann&#39;s involvement has extended into the Rugby World Cup 2023-2027 cycle
He participated in the July triumphs over Hong Kong in Talca and Belgium in Viña del Mar
he featured in matches against Scotland in July and the Argentina XV in September
he was not part of the recent Rugby World Cup 2027 Qualifier against Paraguay
during which Pro D2 player Bruno Sáez made his debut for Chile
The imminent arrival of the 27-year-old Eissmann at Agen is expected to bring immediate integration into the team
His presence in the team brings the expectation of potentially forming a formidable second-row partnership with Canadian Evan Olmstead
the club also boasts the presence of former Pumas hooker Santiago Socino
<a data-mm-click-analytics="true" data-vars-action="click" data-vars-label="https://www.si.com/onsi/rugby/authors/judy-rotich" data-vars-category="default category" data-vars-type="click" href="https://www.si.com/onsi/rugby/authors/judy-rotich">JUDY ROTICH</a>
The content on this site is for entertainment and educational purposes only
Betting and gambling content is intended for individuals 21+ and is based on individual commentators&#x27; opinions and not that of Sports Illustrated or its affiliates
All picks and predictions are suggestions only and not a guarantee of success or profit
If you or someone you know has a gambling problem
crisis counseling and referral services can be accessed by calling 1-800-GAMBLER
For the complete transcript of the earnings call, please refer to the <a href="https://www.gurufocus.com/stock/AGEN/transcripts/2598946" target="_blank" rel="noreferrer noopener">full earnings call transcript</a>
a pioneering biotechnology company specializing in immunological agents for cancer treatment
has announced it will release its financial results for the first quarter of 2025 before the market opens on Monday
The announcement will be followed by a conference call and webcast at 8:30 a.m
where company executives will provide in-depth insights into the financial results and other corporate updates
Interested parties can register for the conference call and find access information on Agenus' investor relations page
Agenus is recognized for its comprehensive pipeline aimed at expanding immunotherapy benefits to wider cancer patient populations
The company leverages a robust suite of antibody therapeutics
adoptive cell therapies via MiNK Therapeutics
Agenus maintains cutting-edge commercial and clinical cGMP manufacturing facilities
investors are encouraged to follow Agenus’ official website and social media channels
the company continues to caution stakeholders regarding forward-looking statements
which involve risks and uncertainties that could lead to actual results differing significantly
These risks are detailed in Agenus' most recent Annual Report on Form 10-K for 2023 and subsequent Quarterly Reports on Form 10-Q
Agenus emphasizes that these forward-looking statements are made as of the press release date and assumes no obligation to update them unless legally required
By <a href="https://www.fruitnet.com/maura-maxwell/89.bio" rel="author">Maura Maxwell</a>2025-02-20T11:25:00+00:00
Chile anticipates a positive D’Agen plum export campaign this year
although shipments could be somewhat lower than last year
“The weather conditions are all in place to have a good season
The key for us is that the rules are respected so that the harvest is favourable,” Ignacio Caballero
executive director of the Chilean Stonefruit Committee
told El Mercurio’s El Campo Magazine at the beginning of February
so it is very important to harvest according to Chilean standards and quickly bring the fruit into cold storage to be able to extend the life of the product.”
Chile exported 89mn (9kg) cartons of D’Agen plums
leading to a significant increase in planted area
Chile currently has around 13,350ha of production
Total production of Chilean D’Agen plums (fresh and dried) is expected to reach 100,000 tonnes this season
of which around 70 per cent will be sent to China
7.38mn cartons of plums had been shipped by the third week of 2025
around 8 per cent less than in the same period last year
Cabellero said the drop in shipments is likely due to producers preferring to use their harvest for dehydrated products
“The advantage of European plums is that they have a very good price for both fresh and dehydrated products
so producers can make decisions week by week about whether they are going to export the product fresh or dehydrated
this depends on a commercial decision,” he explained
said fresh prices were not so good last year
which could result in a smaller quantity of fresh fruit being exported this year
until now everything that has been done has been done well
we hope that this one will be better than the last one but we are cautious,” Caballero said
Cultivation of D’Agen plums has become more technical in the country
with more high density planting and increasing mechanisation
Chile has a competitive advantage in plums as there is not much competition from other sources when its production hits the market
and this creates a good market for counterseasonal product
If China buys its 370,000 tonnes at good prices
it should perfectly be able to buy our 70,000 tonnes that we send fresh at a good price,” Valdés said
Site powered by <a href="https://www.abacusemedia.com/webvisioncloud">Webvision Cloud</a>
recently showcased significant findings from the NEOASIS study at the American Association for Cancer Research (AACR) Annual Meeting in Chicago
The study assessed the efficacy of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for multiple solid tumors
marking the third clinical evaluation of these agents
The NEOASIS Phase 2 trial involved patients with non-metastatic solid tumors
categorized into two cohorts: mismatch repair–deficient (dMMR/MSI-H) and mismatch repair–proficient (pMMR/MSS)
Results highlighted a 90% pathological response rate for the dMMR/MSI-H cohort and an 80% response rate for the pMMR/MSS cohort
63% of patients in the triple-negative breast cancer subgroup achieved a major pathological response (MPR)
the study observed no dose-limiting toxicities
ensuring all participants proceeded to surgery without delay
emphasized the substantial potential of BOT/BAL in early-stage cancer treatments
especially for tumors resistant to traditional immunotherapies
For additional information on the NEOASIS study and other clinical trials involving botensilimab and balstilimab
interested parties can visit the company’s dedicated resources
which spans a relatively short 163.5 kilometers from Agen to Pau
This region will host significant battles for the overall classification on Saturday and Sunday
the sprinters will likely have their second-to-last chance to vie for a stage win
as the terrain is not particularly demanding
This classic transition stage takes the riders from Agen to the Pyrenees
Although the profile initially appears suited for sprinters
the relatively short 165.3-kilometer race includes 2,000 meters of elevation gain
Most of this climbing is concentrated in the final 40 kilometers
Following a climb to Lasserre at kilometer 121.9
the first categorized climb of the day begins: 1.5 kilometers long with an average gradient of 6.9 percent
leading to the Côte de Blachon at kilometer 127
the road rises again to the category-four Côte de Simacourbe (1.8 kilometers at 6.4 percent)
Mathieu van der Poel’s Canyon Aeroad CFR: The Bike Behind His Spring Classic Wins
Mathieu van der Poels Cyclocross Calendar 2024/2025
Season Review 2024: Great Success of Team Alpecin-Deceuninck
Our #1 AI Stock Pick is on a <a href="https://www.insidermonkey.com/blog/ai-fire-sale-insider-monkeys-1-ai-stock-pick-is-on-a-steep-discount/" style="font-weight: bold;">steep discount</a> - 29.99$ instead of 99.99$! <a href="https://www.insidermonkey.com/blog/ai-fire-sale-insider-monkeys-1-ai-stock-pick-is-on-a-steep-discount/" style="font-weight: bold;">Click here</a> to access exclusive research
Agenus Inc. (NASDAQ:<a href="https://www.insidermonkey.com/insider-trading/company/agenus+inc/1098972/">AGEN</a>) Q4 2024 Earnings Call Transcript March 11
Operator: Good morning and welcome to Agenus Inc.&#x2019;s Fourth Quarter and Year-End 2024 Earnings Conference Call
Currently all participants are in a listen-only mode
and welcome to Agenus&#x2019; fourth quarter and year-end 2024 financial results and corporate update call
A copy of the press release is available on our website at www.investors.agenusbio.com
I&#x2019;d like to remind everyone that today&#x2019;s discussion will include forward-looking statements
These statements are subject to risks and uncertainties
which may cause actual results to differ materially from expectations
Chief Commercial Officer; Christine Klaskin
Finance and Principal Financial and Accounting Officer
Now I&#x2019;ll turn the call over to Garo
Garo Armen: A very good morning once again from a delightful day in Lexington
pleased to report that we delivered on our commitment to significantly reduce the Agenus&#x2019; operational burn
And now we are executing on our next stage of strategic cost reductions with an annualized burn to approximate $50 million by the middle of this year
and we&#x2019;re very much on track for that number
Our objective is to direct every available resource towards what truly matters to our stakeholders and patients particularly
to make sure that our groundbreaking potential of BOT/BAL is realized and patients have access to it as soon as possible
 BOT/BAL continues to demonstrate unprecedented clinical activity
was the first year that AACR organized the immuno-oncology division of its annual conference
And we detail the most influential peer reviewed journals
Journal of Clinical Oncology and Cancer Discovery
All these were accomplished in the last 12 months or less
We are witnessing transformative clinical outcomes in colorectal cancer and other tumors that have been historically unresponsive to immunotherapy
BOT/BAL has demonstrated durable and I want to underline durable responses and prolonged survival in refractory microsatellite stable colorectal cancer
is accounting for these days over 90% of CRCs
We&#x2019;ve seen encouraging activity with the addition of BOT/BAL through FOLFOX
We have also either seen complete or near complete pathological responses
Very importantly in neoadjuvant MSS as well as MSI CRC
we believe based on the results that we have seen
This has transformative potential to enable chemo
and possibly surgery free options for patients
based on the opinion of our experts are beyond promising
these outcomes aren&#x2019;t just our internal assessment
all we need to do is just provide product for them and we incur no cost
This independent validation by some of the most respected oncologists and oncology centers who are pivotal in securing approval in our breakthrough therapies significantly amplify our confidence in BOT/BAL and its potential for patients
are expected to rapidly enroll in potentially organ sparing trials with BOT/BAL
we have a new trial that&#x2019;s gotten underway this week with inquiries that had come in from patients ahead of the official opening of the trial
we&#x2019;ve strategically continued monitoring and monetizing the potential of our non-core assets
Our high value biologics manufacturing facility in Emeryville and Berkeley
our land in Vacaville to fortify our balance sheet currently
We&#x2019;re engaged in also late stage partnership discussions to secure funding for BOT/BAL and BOT/BAL development and registration
With an emphasis on neoadjuvant treatment of early stage
but intermediate stage colon and rectal cancers
where these are clear opportunities for BOT/BAL to provide significant benefit to patients
I&#x2019;ll turn it over to Christine for a quick review of our financials
I&#x2019;ll now turn the call back to Garo
while we recognize that our financial position is not reflective of the high potential on the promise of our product
we are taking decisive actions to continue to and we will continue to take
very decisive actions to bolster our cash position as well as to contain costs
Now we&#x2019;re very heartened by the fact that we&#x2019;ve had significant external validation through numerous selected high quality centers that are doing trials
and robust clinical activity that we have seen in BOT/BAL
position us to advance our LEAD programs in 2025 and beyond
 This is very important because having treated now well over 1,000 patients across nine different cancers with a heavy concentration on colon cancer and seen the benefit to patients
It&#x2019;s very heartening that we have kept our eye on developing BOT/BAL as a high priority for us
Operator: [Operator Instructions] Our first question will come from the line of Emily Bodnar with H.C
and especially into mid-2025 as you&#x2019;re guiding to additional cost cuts
if you can kind of walk us through expected catalyst for 2025 and any new data updates or regulatory updates that we should be looking out for
the cost reductions really center around headcount reductions
experts we need internally and externally and we have significantly cut down on external advisers
We have limited external advisers to those that will benefit us the most in terms of advancing BOT/BAL through a line of registration
And most of the registration work that we were undertaking under accelerated approval is already completed
we will utilize a lot of the work that has been completed
 We have simply shelved them for the time being
and we&#x2019;ve done it in a way that we can reignite them
number of products back from our partners after they have spent in excess of $800 million collectively on those products
Not because of any product performance issues
but strictly because of the fact that IO for the time being is out of fashion
Not because we believe our products are implicated in it being out of fashion
IO is cold and that doesn&#x2019;t mean that it will remain cold three to six months from now
So we have put them on hold with an intent to reignite them quickly
In terminal catalyst for 2025 on the regulatory updates
Operator: [Operator Instructions] And our next question comes from the line of Mayank Mamtani with B
Thanks for taking our questions and appreciate the detailed update here
Maybe just a similar question as asked before on the process of monetization of non-core assets
our Berkeley facility came in the form of a mortgage that we obtained
But we got a $20 million mortgage at a record time of in approximately two weeks
And so that was the first stage of monetization
know that Emeryville is a highly desired state-of-the-art manufacturing facility that is super nuts
It starts with cell lines and it finishes with packaging
given the fact that there has been significant shifts in US Manufacturing interest
We have seen a similar level of interest and we are in discussions
with parties or the potential consummation or monetization of our West Coast manufacturing and real estate asset
And then are you able to share your latest and greatest thoughts on what a registrational program could look like
ASCO-GI data recently showed you know a number of different directions you could go in
could be helpful for folks to understand the path to market here
we have a mess at an enormous amount of data in the late stage setting
There&#x2019;s no ambiguity about our ability to rescue patients with MSS CRC who had exhausted all other options
even though we haven&#x2019;t done a randomized trial in late stage yet
orders of magnitude longer than patients who have
So we have more than double the response rates in these patients
large batch that is based on our current data
essentially double what you would see with standards of care
we have patients who are going on disease free now
that&#x2019;s one area where with more mature data
And what we&#x2019;re seeing is complete pathological responses in more than half patients
there was some concern that the data was from a single center
But now the data corroborates the Cornell data in 11 centers from Europe and in four times the patients
 Because of the black and white nature of the outcomes in MSS CRC and MSI High
particularly in a setting that will be organ sparing
And we believe that if we can show that our products are organ sparing
In the refractory setting that between our Phase 1 and our Phase 2 trial
Those trials have closed and the data is maturing
And we look forward to really watching this durability of response and treatment free interval mature and then obviously interact further with regulatory bodies around this data
And then I think what Garo said in the neoadjuvant setting is really remarkable in terms of its ability to change paradigms in both the MS Stable and obviously the MS-High colorectal setting
And rectal cancer is within our sites as a primary first neoadjuvant sort of regulatory approach
Looking at some of these updates in the coming months
I think the context has been explained certainly in terms of
but I would also point out that both rectal and colon cancer have a significant opportunity
in rectal cancer potential for chemo sparing
because if we improve the clinical complete response rate
those patients basically will not go into surgery
They&#x2019;ll wait and the evidence that we&#x2019;ve seen so far with early use of immunotherapy particularly CTLA-4 translates into a prolonged recurrence free survival
we expect we&#x2019;re going to be able to improve the rectal cancer
there is that opportunity to be able to improve the event free survival
And real question about being able to reduce the amount of chemotherapy the patients are receiving
the potential for permanent neuropathy in the long run
had infants chemotherapy may end up with a permanent neuropathy that could be avoided
and that coupled with the ability to improve on
event free survival and overall survival really makes colon cancer a real significant opportunity as well
just there&#x2019;s an IST that&#x2019;s just initiated Memorial Sloan Kettering
Operator: And that will conclude our question-and-answer session
I&#x2019;ll hand the call back over to Garo Armen for any closing remarks
It&#x2019;s always a pleasure to have you and your questions
We&#x2019;re very excited about the prospects of our LEAD programs
And so we&#x2019;re grateful to our investigators and patients for participating in these trials to demonstrate the kind of results that we&#x2019;ve come up with so far
Operator: And that will conclude today&#x2019;s conference call
<a href="https://www.insidermonkey.com/blog/tag/q4-2024/" rel="tag">Q4 2024</a><a href="https://www.insidermonkey.com/blog/tag/msn-news/" rel="tag">MSN News</a><a href="https://www.insidermonkey.com/blog/tag/nasdaqagen/" rel="tag">NASDAQ:AGEN</a><a href="https://www.insidermonkey.com/blog/tag/earnings-call-transcript/" rel="tag">Earnings Call Transcript</a>
Artificial intelligence is the greatest investment opportunity of our lifetime
The time to invest in groundbreaking AI is now
My #1 AI stock pick delivered solid gains since the beginning of 2025 while popular AI stocks like NVDA and AVGO lost around 25%
The numbers speak for themselves: while giants of the AI world bleed
showcasing the power of our research and the immense opportunity waiting to be seized
Artificial intelligence isn’t science fiction anymore
It&#8217;s the revolution reshaping every industry on the planet
From driverless cars to medical breakthroughs
and savvy investors stand to reap the rewards
Here&#8217;s why this is the prime moment to jump on the AI bandwagon:
Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory
and automated logistics that streamline everything
This isn&#8217;t a maybe – it&#8217;s an inevitability
Early investors will be the ones positioned to ride the wave of this technological tsunami
Ground Floor Opportunity: Remember the early days of the internet
Those who saw the potential of tech giants back then are sitting pretty today
We&#8217;re not talking about established players – we&#8217;re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon
This is your chance to get in before the rockets take off
Disruption is the New Name of the Game: Let&#8217;s face it
and it&#8217;s shaking the foundations of traditional industries
while the dinosaurs clinging to outdated methods will be left in the dust
The Talent Pool is Overflowing: The world&#8217;s brightest minds are flocking to AI
From computer scientists to mathematicians
the next generation of innovators is pouring its energy into this field
This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements
you&#8217;re essentially backing the future
The future is powered by artificial intelligence
Don&#8217;t be a spectator in this technological revolution
Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation
This isn&#8217;t just about making money – it&#8217;s about being part of the future
buckle up and get ready for the ride of your investment life
Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)
and savvy investors stand to make a fortune
how do you find the hidden gem – the company poised for explosive growth
that even if its stock price quadrupled today
it would still be considered ridiculously cheap
That&#8217;s the potential you&#8217;re looking at
This isn&#8217;t just about a decent return – we&#8217;re talking about a 10,000% gain over the next decade
Our research team has identified a hidden gem – an AI company with cutting-edge technology
and a current stock price that screams opportunity
This company boasts the most advanced technology in the AI sector
It&#8217;s like having a race car on a go-kart track
They have a strong possibility of cornering entire markets
becoming the undisputed leader in their field
Here&#8217;s the catch (it&#8217;s a good one): To uncover this sleeping giant
We want to make sure none of our valued readers miss out on this groundbreaking opportunity
That&#8217;s why we&#8217;re slashing the price of our Premium Readership Newsletter by a whopping 70%
For a ridiculously low price of just $29.99
you can unlock a year&#8217;s worth of in-depth investment research and exclusive insights – that&#8217;s less than a single restaurant meal
Here&#8217;s why this is a deal you can&#8217;t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock&#8217;s groundbreaking technology and massive growth potential
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter&#8217;s portfolio over the next 12 months
These stocks are handpicked by our research director
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads
allowing you to focus on uncovering the next big opportunity
• 30-Day Money-Back Guarantee:  If you&#8217;re not absolutely satisfied with our service
we&#8217;ll provide a full refund within 30 days
Space is Limited! Only 1000 spots are available for this exclusive offer. Don&#8217;t let this chance slip away – <a href="https://www.insidermonkey.com/checkout_v2/subscription/10/?code=PR5BA">subscribe to our Premium Readership Newsletter today</a> and unlock the potential for a life-changing investment
1. Head over to our website and <a href="https://www.insidermonkey.com/checkout_v2/subscription/10/?code=PR5BA">subscribe</a> to our Premium Readership Newsletter for just $29.99
exclusive access to our in-depth report on the revolutionary AI company
and the upcoming issues of our Premium Readership Newsletter over the next 12 months
and know that you&#8217;re backed by our ironclad 30-day money-back guarantee
Don&#8217;t miss out on this incredible opportunity
Subscribe now and take control of your AI investment future
I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries
We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…
Should I put my money in Artificial Intelligence
Here to answer that for us… and give away his No
1 free AI recommendation… is 50-year Wall Street titan
He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC
But what Marc’s most known for is his award-winning stock-rating system
Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down
That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…
and brokerages to track the billions of dollars flowing in and out of stocks each day
He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022
<a href="http://track.ic3trk.com/aff_c?offer_id=4449&amp;aff_id=1198" class="external" rel="nofollow">Click to continue reading&#8230;</a>
Get our editor’s daily picks straight in your inbox
Sign up for our daily Newsletter and stay up to date with all the latest news
You are receiving this pop-up because this is the first time you are visiting our site
You are using software which is blocking our advertisements (adblocker)
we are relying on revenues from our banners
So please disable your adblocker and reload the page to continue using this site.Thanks
the renowned variety used for producing Agen PGI prunes
Secretary General of the Bureau National Interprofessionnel du Pruneau (BIP)
provided an update on this year's campaign
But Not Catastrophic""We can't call it a great harvest
unlike the 2021 and 2022 seasons," says Gaëtan Vergnes
with yields returning to 40,500 tonnes (including 32,000 for PGI prunes)
initial estimates (pending confirmation) suggest a 20-30% decline compared to last year
meaning approximately 120,000 tonnes of fresh plums were harvested
resulting in around 40,000 tonnes of prunes
and processed within six South-Western departments—Tarn et Garonne
and Gironde—representing 99% of France's prune production
only the largest prunes meet the PGI specifications
Excess Water and Root AsphyxiaWhat caused the drop
particularly hailstorms and heavy rains in the PGI zone
which caused tree deaths," Vergnes explains
even if the sugar content is lower than in previous years
A Short HarvestThe 2024 harvest lasted between three weeks and a month
"a relatively short duration compared to industry norms," according to Gaëtan Vergnes
"There were significant losses due to storms and wind
which caused many plums to fall from the trees all at once
harvesting is fully mechanized (except in the organic sector)
"Manual harvesting requires too much labor with no real benefit today," Vergnes concludes
For more information:Bureau National Interprofessionnel du Pruneau2 rue des Magnolias47303 Villeneuve-sur-Lot Tel. 05 53 41 55 55<a translate="no" href="/cdn-cgi/l/email-protection#a4c3c5c1d0c5ca8ad2c1d6c3cac1d7e4d4d6d1cac1c5d18ac2d69bd7d1c6cec1c7d099f6670dc5c7d0cdcbca84670484c883c5d6d0cdc7c8c184c0c184e2d6c1d7ccf4c8c5dec58ac2d6" target="_blank" rel="noopener">[email&#160;protected]</a>
FreshPublishers &#xA9; 2005-2025 FreshPlaza.com
Looking for a northern Michigan event this weekend
Browse our comprehensive list of things to do in northern Michigan and discover exciting activities tailored to every interest
From outdoor escapades to cultural experiences
our events page showcases the best northern Michigan events this weekend across the region
 Whether you're a local seeking adventure or a visitor exploring our beautiful area
we've curated a selection of northern Michigan events this weekend that cater to all ages and preferences
Dive into our extensive calendar today and start planning your perfect northern Michigan getaway!\n  
The Sweden-based retail giant IKEA is the go-to home furniture store for many customers with 479 locations all around the globe
IKEA offers a ton of styles at various price points
ensuring that people with a wide array of interior design wants and budgets can find what they need
Its huge catalog includes dozens of armchairs in every color
it can also make it more difficult to know which ones will stand the test of time
and act as a fashionable addition to your space
we scoured IKEA's site to find the best and the worst of their armchair options
looking to reviews from real life customers to tell us the various pros and cons of the chairs
We also made sure to include several specific factors that might guide the average shopper in their search
and whether or not they have a comfortable and ergonomic design
For every armchair that didn't quite hit the needs of our readers and IKEA customers
Read on to see our full list of must-have and must-miss IKEA armchairs
While ergonomic chairs often have pared-down frames for enhanced comfort, the <a href="https://www.ikea.com/us/en/p/arsunda-armchair-knisa-light-gray-30535897/" target="_blank">ÄRSUNDA armchair</a> manages to look exceptionally flimsy
That's thanks to the incredibly thin cushion that serves as the sole back and seat support
this chair is not easy to put together if you follow IKEA's infamous illustrated instructions
"Everyone loves its comfort from the children to the grandparents
I came to the website to buy our third one for another room
The grandparents took our second one for themselves!"
I followed the instructions to use a damp cloth
Any attempt to get rid of it made it worse
the chair looks horrible from other minor spills including water
It also has pilled just from sitting on it." Sadly
being easy to stain and difficult to keep looking great makes this chair a must-miss
deep seat makes it very spacious and easy to relax into
The <a href="https://www.ikea.com/us/en/p/finnala-armchair-grann-bomstad-black-s89505153/" target="_blank">FINNALA Armchair</a> is stylish
and with the contact areas made of genuine leather
it's definitely worth more than most fabric-covered IKEA furniture
This armchair is both meant to match with the FINNALA modular sectional seats and act as a standalone piece
An entire 3-person sofa from this collection in the same material and color costs just $1,599
which is a much better value in our opinion
Unless it's vitally important to you that your couch and armchair match perfectly, you could consider instead choosing the <a href="https://www.ikea.com/us/en/p/morabo-armchair-grann-bomstad-golden-brown-wood-s19317476/" target="_blank">MORABO Armchair</a>
It provides a similar silhouette as the FINNALA and is made of the same leather and fabrics
The most significant difference between the two
a whopping $200 less than the FINNALA model
despite its tightly woven seat and backing
One reviewer reported that they have had to replace their husbands chair twice now because it couldn't support his weight over the long term
Other reviewers said that the finish varies from chair to chair
The <a href="https://www.ikea.com/us/en/p/holmsta-armchair-handmade-beige-90508551/" target="_blank">HOLMSTA Armchair</a> has very positive reviews on its listing on IKEA
both for the models with and without cushions
Customers say that both options look great
While this option is a bit more expensive than the AGEN
its comparatively sturdy structure will ensure that you won't have to shell out money on a replacement in a few years
"[The cover] gaps and creases across the arms and back
not even fitting against the back of the chair
I will have to exchange the cover to try a new one; if that fits the same way
I will return the whole chair." Another noted that even after ironing the cover
it wrinkled terribly when placed over the cushions
Slip cover furniture already runs the risk of looking a bit shabby chic
so ill fitting cushions and covers make for a very unflattering chair
Looking for something similar to the TULLSTA that won't disappoint after unboxing? We love the <a href="https://www.ikea.com/us/en/p/backsaelen-1-5-seat-armchair-blekinge-white-s29393200/#content" target="_blank">BACKSÄLEN armchair</a> from IKEA for its classic slip cover style and slightly more contemporary silhouette
The cover can also be machine washed for easy maintenance
it's made of 100% cotton that is safe to iron
Add articles to your saved list and come back to them any time
France’s budget OUIGO train service uses the same mechanics as the original TGV and travels at incredible speeds of up to 320km/h
Travelling across France on the high-speed OUIGO service
Paris Gare Montparnasse to Agen on SNCF’s OUIGO service with a scheduled time of three hours
aboard a 16-car Grande Vitesse high-speed train
“One single class” has got to be a synonym for “We pack you in like sardines”.Credit: Alamy
SNCF’s budget high-speed train product that can transport up to 1260 passengers at a time
Taking a leaf out of the low-cost airline business
or cherry-pick the extras that are relevant to you
Wi-Fi access or even taking a bike on board
Children’s fares are advertised as between €5 and €8 ($8 and $13) no matter the destination (we are travelling as a family of four and pay €8 per child)
so they still have the same pointy nose and split-level
yet are distinguished by their bright blue and pink livery and are stripped back
the original TGV service is sold as TGV InOui
first- and second-class options and fewer passengers
compared with 113.9 kilograms if flying from Paris Orly to Agen
Gare Montparnasse train station in Paris.Credit: Bloomberg
There’s nothing like waking up on the morning of your departure to an email from SNCF titled “urgent”
Our carriage has been removed from service and we have been allocated four new seats
which is hardly ideal when two of our party are under 10
When I call SNCF customer service I’m told that this is the best configuration available
is to “ask people to swap seats with us when we board”
We find a better solution when we arrive at the platform and make a beeline for the inspector
It’s also the only one that doesn’t have a door
but we enter from car 15 and nab the last free quad seats
SNCF says the secret to OUIGO’s optimised space is one single class
but that’s got to be a synonym for “we pack you in like sardines”
It’s worth paying the extra €7 ($11.50) to reserve your seat (or booking the OUIGO Plus fare) if you’re travelling alone to ensure you don’t end up in the middle seat of a cosy triplet row
a configuration never used on a classic TGV
The seats in our carriage are all quads and are comfortable enough
The onboard Wi-Fi is rather cutely called OUIFI — but it cuts in and out across our journey
Although one backpack and one small piece of under-seat luggage is all that’s included in the base fare
for the moment OUIGO staff remain blissfully ignorant of the inquisition-like baggage checks Europe’s budget airlines carry out before anyone is allowed to board their aircraft
No one at the station seems to blink an eye at what anyone is bringing on board
The bar on the TGV is one of my great transport pleasures and it took my daughter and I walking through every carriage on the inbound leg from Agen to Paris a few days earlier to realise that there’s no food and beverage service on the OUIGO
at a Monoprix supermarket in Montparnasse before our departure
but the mechanics work the same and this is still a train that travels at incredible speeds of up to 320km/h
We leave on time and arrive 10 minutes late into Agen
owing to an unexplained stop on the track outside Paris
It’s not the most comfortable or relaxing train journey I’ve ever had
but we make it to our destination having saved €200 ($325) on the more expensive TGV InOui fare
I end up with €12 ($20) in travel vouchers as compensation for the seating changes
If you don’t mind frill-free travel – and can cope with last-minute surprises – OUIGO can be a great deal for crisscrossing France by high-speed rail for less
The latest travel news, tips and inspiration delivered to your inbox. <a class="vf-Bg" href="https://login.myfairfax.com.au/signup_newsletter/10078?channel_key=zHE9EWDHf1XPuz3Phk0YIg&amp;callback_uri=">Sign up now</a>.
France\\u2019s budget OUIGO train service uses the same mechanics as the original TGV and travels at incredible speeds of up to 320km/h.
Paris Gare Montparnasse to Agen on SNCF\\u2019s OUIGO service with a scheduled time of three hours, 45 minutes, aboard a 16-car Grande Vitesse high-speed train.
Five kilograms a passenger, compared with 113.9 kilograms if flying from Paris Orly to Agen.
There\\u2019s nothing like waking up on the morning of your departure to an email from SNCF titled \\u201Curgent\\u201D. Our carriage has been removed from service and we have been allocated four new seats, but nowhere near each other, which is hardly ideal when two of our party are under 10.
Although one backpack and one small piece of under-seat luggage is all that\\u2019s included in the base fare, for the moment OUIGO staff remain blissfully ignorant of the inquisition-like baggage checks Europe\\u2019s budget airlines carry out before anyone is allowed to board their aircraft. No one at the station seems to blink an eye at what anyone is bringing on board.
The bar on the TGV is one of my great transport pleasures and it took my daughter and I walking through every carriage on the inbound leg from Agen to Paris a few days earlier to realise that there\\u2019s no food and beverage service on the OUIGO, not even a snack trolley. For this return journey, we stock up on snacks, probably a bit too enthusiastically, at a Monoprix supermarket in Montparnasse before our departure.
It may be the budget version, but the mechanics work the same and this is still a train that travels at incredible speeds of up to 320km/h.
Copyright © 2025 FactSet Research Systems Inc.© 2025 TradingView
so that's an achievement that won't be missed by us
but we know we've got three more games to keep building on that." 
 Henry Pollock and his band of brothers pulled off a remarkable heist in Dublin on Leinster to make them believe anything's possible 
The referee has blown their whistle to end the game
This is dangerous for the defence as Iban Etcheverry bursts through to advance the Agen attack
Provence Rugby decide to make a substitution
Jimmy Gopperth takes the penalty but the ball didn't come round
Agen make a substitution with Jack Maunder coming on
Agen make a substitution with Dorian Bellot coming off
Agen sub Fotu Lokotui comes onto the field
Provence Rugby sub Kevin Viallard comes onto the field
The Provence Rugby supporters go wild as Jimmy Gopperth successfully kicks the conversion
And they do with Josh Tyrell touching down
Spellbinding play by Charly Gambini is finished off with a try
The defensive line has been broken as Arthur Coville goes through the gap
Agen sub Peyo Muscarditz comes onto the field
Agen sub Lucas Martins comes onto the field
Hayden Thompson-Stringer comes on for Provence Rugby
with Jimmy Gopperth getting some game time
awarding the penalty try to Provence Rugby
Franck Pourteau (Agen) is shown a yellow card
Inga Finau makes the break as the defence re-enacts the parting of the red sea
Agen make a substitution with Evan Olmstead coming on
Agen make a substitution with Javier Eissmann coming off
The half-time whistle blows and both teams head for the dressing rooms
Hans Lombard-Buret (Agen) is shown a yellow card
Franck Pourteau makes no mistake with that conversion attempt
A wonderful passing move by Agen is finished off by Clement Garrigues
That's a great try assist by Franck Pourteau
This is dangerous for the defence as Franck Pourteau bursts through to advance the Agen attack
This is dangerous for the defence as Joseph Laget bursts through to advance the Provence Rugby attack
Franck Pourteau does the business as their penalty goal attempt goes over
The defensive line has been broken as Nadir Bouhedjeur goes through the gap
We are underway as the referee blows their whistle
 Join free and tell us what you really think
 George North has finally opened his try-scoring account for Aix-en-Provence in the Pro D2
crossing the whitewash in Round 22 agai&hellip; 
 The Fijian fly-half hasn't been short of offers from France
with Pro D2 outfit Provence favourites to land his signature
 Kapeli Pifeleti describes his departure from Saracens as “inevitable”
Making 53 appearances in almost six years at StoneX Sta&hellip; 
 The upcoming Pro D2 season sees some absolute giants across the league
with the French second flight rivalling the Top 14
- Jarrod Agen who served as a the Director of Communications and Chief of Staff to the Office of Governor Rick Snyder was arraigned in court
Agen is facing charges related to the Flint Water Crisis
READ MORE:<a href="https://nbc25news.com/news/local/flint-water-prosecution-team-will-announce-findings-in-investigation" target="_blank" title="https://nbc25news.com/news/local/flint-water-prosecution-team-will-announce-findings-in-investigation" class="themeColorForLinks">Flint Water prosecution team announces findings in investigation into water crisis</a>
Nine were indicted on charges by Solicitor General Fadwa Hammoud and Prosecutor Kym L
Worthy as part of the criminal investigation into the Flint Water Crisis
Agen is charged with one-count of perjury which is a 15-year felony
READ MORE:<a href="https://nbc25news.com/news/flint-water-woes/two-10000-bonds-set-for-former-gov-snyder-in-flint-water-case" target="_blank" title="https://nbc25news.com/news/flint-water-woes/two-10000-bonds-set-for-former-gov-snyder-in-flint-water-case" class="themeColorForLinks">Two $10,000 bonds set for former Gov. Snyder in Flint water case</a>
Agen waived the right to a formal reading and plead not guilty to the charges
His pre-trial exam will be held on February 18 at 3:00 p.m
Welcome to our dedicated page for Agenus news (Ticker: AGEN)
a resource for investors and traders seeking the latest updates and insights on Agenus stock
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases
This page provides centralized access to official press releases
offering stakeholders a reliable resource for tracking the company’s progress
Investors and researchers will find timely updates on clinical trial milestones
alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology
The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities
Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators
and vaccine adjuvants without navigating multiple sources
a leading immunological cancer treatment developer
has scheduled its first quarter 2025 financial results announcement for Monday
The company will host a conference call and webcast at 8:30 a.m
featuring company executives who will discuss quarterly results and provide a corporate update
Interested parties can access the event through:
A replay of the conference call will be made available through both the company website and Q4's platform for those unable to attend the live session
Agenus presented promising results from their NEOASIS study at the AACR Annual Meeting
showcasing the effectiveness of their botensilimab and balstilimab (BOT/BAL) combination therapy in treating various solid tumors
Key findings from the Phase 2 neoadjuvant study include:
The study demonstrated that just two doses of BOT/BAL could induce significant responses across multiple cancer types
and all patients proceeded to surgery as scheduled
The treatment shows particular promise in early-stage cancers
including those typically resistant to immunotherapy
Agenus (NASDAQ: AGEN) presented updated data from its Phase 1 study evaluating the combination of botensilimab (BOT) and balstilimab (BAL) in hepatocellular carcinoma (HCC) at the AACR Annual Meeting
The study focused on 19 heavily pretreated patients who had progressed after standard treatments
Key results from the trial showed:Overall response rate: 17%Disease control rate: 72%Median progression-free survival: 4.4 monthsMedian overall survival: 12.3 months
The BOT/BAL combination demonstrated durable responses in treatment-refractory HCC patients
including those who progressed on atezolizumab/bevacizumab
The safety profile remained consistent with previous cohorts and was manageable
The study results suggest potential clinical utility in treating advanced HCC patients who have  options after progression on immune checkpoint inhibitors
Agenus (Nasdaq: AGEN) announced three upcoming presentations at the 2025 ASCO Annual Meeting in Chicago (May 30 - June 3)
The presentations include new translational data on botensilimab and balstilimab (BOT/BAL) in colorectal cancer and two trials-in-progress studies
The first presentation focuses on T-cell dynamics monitoring in mismatch repair-proficient/microsatellite stable metastatic colorectal cancer
The other two presentations detail ongoing clinical studies of botensilimab-based combinations in advanced pancreatic cancer: one examining botensilimab with AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody)
and another investigating a combination therapy including botensilimab
Agenus (Nasdaq: AGEN) has announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30
highlighting their neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL)
The presentations include:An oral presentation of initial results from the NEOASIS trial studying BOT/BAL in MMR proficient and deficient early-stage cancers
Myriam Chalabi from Netherlands Cancer Institute on April 28
2025A poster presentation featuring new data from the Phase 1 study of BOT/BAL in treatment-refractory hepatocellular carcinoma (HCC)
Anthony El-Khoueiry from USC Norris Comprehensive Cancer Center on April 29
These presentations build upon previous BOT/BAL data from two independent studies (UNICORN and NEST) in colorectal cancer presented earlier at ASCO-GI
Agenus (NASDAQ: AGEN) has released findings from its national Colorectal Cancer in Focus survey
revealing critical gaps in current treatment options
gathered insights from patients and healthcare providers (HCPs) about colorectal cancer (CRC) care
Key findings show that over 50% of HCPs reported increased CRC diagnoses in adults under 50
with 82% of surveyed patients diagnosed before that age
An overwhelming 93% of HCPs believe current CRC treatments are insufficient
The survey highlighted that 61% of patients expressed interest in non-chemotherapy treatments
while 37% of HCPs identified immunotherapy as the most promising advancement in CRC treatment
conducted in partnership with the Colorectal Cancer Alliance and Fight Colorectal Cancer
emphasizes patients' prioritization of quality of life
with one-third citing minimal life impact as a top treatment priority
Most patients reported chemotherapy and radiation side effects as their most challenging aspect of treatment
Agenus (NASDAQ: AGEN) has reported its Q4 and full-year 2024 financial results
highlighting significant operational improvements and cost reductions
The company achieved a Q4 2024 operational cash burn of $28.7 million and aims to reduce annual burn to approximately $50 million by mid-2025
The company's botensilimab/balstilimab (BOT/BAL) program demonstrated promising clinical outcomes in resistant tumor types
particularly in colorectal cancer treatment
Data presented at ASCO-GI 2025 showed meaningful
durable responses across neoadjuvant and later lines of CRC treatment
Financial highlights include:Year-end 2024 cash balance of $40.4 million (down from $76.1 million in 2023)2024 revenue of $103.5 millionNet loss of $232.3 million ($10.59 per share)Q4 revenue of $26.8 million with net loss of $46.8 million ($2.04 per share)
(NASDAQ: AGEN) has presented significant immuno-oncology data across multiple medical conferences and publications in 2024-2025
highlighting advances in cancer immunotherapy
have been evaluated in approximately 1,100 patients across 60+ centers worldwide
The BOT/BAL combination has shown clinical responses across nine tumor types
Notable results include:High major pathological response rates in colorectal cancer (CRC) through the NEST and UNICORN trials19% response rate in microsatellite stable (MSS) metastatic CRC patients with no liver metastases71% objective response rate in combination with FOLFOX chemotherapy and bevacizumab in MSS metastatic CRC19.2% overall response rate in sarcoma patients with 69% 12-month survival rate
Riley Securities Precision Oncology & Radiopharma Investor Conference in New York
will join a panel discussion focused on 'What It Takes to Move the Needle in Improving Responses in Colorectal Cancer.' The event is scheduled for February 28th
This in-person conference requires interested attendees to contact B
a leader in developing novel immunological agents to treat various cancers
has announced it will release its fourth quarter and full year 2024 financial results before market opening on Tuesday
Agenus executives will host a conference call and webcast at 8:30 a.m
ET to discuss the results and provide a corporate update
Interested parties can register to access the dial-in numbers with Conference ID: 73242
A live webcast and replay of the conference call will be available on the company's investor relations website and through the provided event link
A three-judge Court of Appeals panel sided with the former chief of staff for Gov
affirming a motion to dismiss a felony perjury charge against Jarrod Agen stemming from the Flint water crisis
but have found mixed results from Court of Appeals panels
who have sided with defense lawyers to affirm in all but one of the cases they've ruled on so far
Presiding Judge Colleen O'Brien issued a <a href=https://www.courts.michigan.gov/48fae4/siteassets/case-documents/uploads/coa/public/orders/2023/363815_19_01.pdf target=_blank>one-sentence order</a> granting a motion to affirm the dismissal made by Agen's attorneys
writing "the questions to be reviewed are so unsubstantial as to need no argument or formal submission." Judges Mark Cavanagh and Kathleen Jansen made up the rest of the panel
Agen was facing a single count of felony perjury
after prosecutors alleged he lied to investigators in 2017
A spokesperson for the prosecution team said they plan on appealing Agen's case to the Michigan Supreme Court
More:<a href=https://www.freep.com/story/news/local/michigan/flint-water-crisis/2022/10/04/flint-water-crisis-charges-dismissed-lyon-peeler-baird/69508869007/ target=_blank>Judge dismisses Flint water crisis cases against ex-officials after Supreme Court ruling</a>
More:<a href=https://www.freep.com/story/news/politics/2022/12/22/flint-water-prosecutors-to-appeal-lyon-case-to-michigan-supreme-court/69751703007/ target=_blank>Flint water crisis prosecutors plan to appeal case for ex-health director to Supreme Court</a>
who later worked on former Vice President Mike Pence's staff after Snyder left office
was one of seven officials who saw charges stemming from the Flint water crisis dismissed in October
who was governor in Michigan from 2011 to 2019
was charged with two counts of willful neglect of duty by a public official
His charges were remanded for dismissal in December
Prosecutors appealed the dismissal in January
Snyder's attorney has filed a motion to dismiss the appeal
Contact Arpan Lobo: <a href=mailto:alobo@freepress.com>alobo@freepress.com</a>. Follow him on Twitter <a href=https://www.twitter.com/arpanlobo target=_blank>@arpanlobo</a>
<a href=https://cm.freep.com/specialoffer/>Become a subscriber today.</a>
Singer and actress Suzy conveyed the aesthetics of daily life
The agency's management forest recently posted concept photos and special photos of Suzy's digital single "Come back" on its official SNS
The concept photos released three times were made in black and white tones
It naturally melted down Suzy's moments in every corner of the house
the special photo expresses Suzy's innocence like a child in color tone
It is the first time in about two years that Suzy has performed a new song
Whenever the teasing contents were unveiled one after another
Suzy also expressed her affection for the entire single production as she met her fans as a singer for the first time in a long time
who has worked with Suzy such as "Satellite" and "Cape," also participated in the work on the song
Suzy's new single "Comeback" will be released on various music sites at 6 p.m
※ This service is provided by machine translation tool
<a href="https://www.postcourier.com.pg/" rel="home">Post Courier</a>
THE Supreme Court has overturned the 11-year conviction of Robert Agen for the alleged rape and assault of his ex-girlfriend over six years ago at Owers Corner in Sogeri
appealed his sentence through his lawyer David Dotaona and was successful after a three-men bench of Chief Justice Sir Gibbs Salika
Justice Paulus Dowa and Justice Teresa Berrigan made the orders acquitting Agen on the conviction of rape and assault on count 1 and 2 of the indictment
According to the decision on the appeal by the court
Agen was convicted following a trial of three charges arising out of two separate incidents involving the same woman
The charges were rape and common assault and Agen was convicted and sentenced to 11 years with hard labour
five and half years of which was suspended
and he had appealed against the conviction on all three counts
The notice of appeal contains 47 grounds which are prolix and repetitive
the first concerns alleged irregularities at the charging or committal stage
which Agen said meant that he was never properly charged by the District Court
and the second challenges the convictions on various grounds
The Supreme Court in considering the charges of the first incident that is said to have occurred at Owers Corner in Sogeri
the court said had inconsistencies in particular on their relationship
which the complainant stated started after the incident at Owers Corner and before the Waigani incident
Agen maintained that they were in a relationship until he terminated the relationship in late 2018 and early 2019
The three-men bench said the inconsistencies were not addressed by the State and was not considered
the verdicts for guilt on the Owers Corner rape and assault charges must be set aside”
Get the latest news delivered straight to your inbox
It's surprising to hear Addison Agen describe the beginning of her journey on NBC's "The Voice" as the "worst audition" of her life
Before the 16-year-old from Fort Wayne caught the attention of Miley Cyrus and Adam Levine
sailed through week after week of televised competition and finished as Season 13's runner-up
Agen tried out with thousands of other hopefuls at Chicago's McCormick Place in January 2017
"I forgot the words and the melody and I about passed out," Agen said of her first attempt to sing Allen Stone's "The Bed I Made." "I had to restart
because I literally had no idea what I was doing
Agen's shaky start is a barely remembered blip for the poised and talented singer who performed "Don't Know Why" with Norah Jones during "The Voice" season finale.&nbsp;
John Mellencamp: <a href=http://www.indystar.com/story/entertainment/music/2018/02/05/10-john-mellencamp-insights-his-new-netflix-film/308046002/>10 insights in Indiana rock star's new Netflix film</a>
Justin Timberlake: <a href=http://www.indystar.com/story/entertainment/music/2018/02/05/justin-timberlake-plans-december-show-indianapolis/306241002/>Pop star plans December show in Indianapolis</a>
Art & Soul: <a href=http://www.indystar.com/story/entertainment/arts/2018/01/31/art-soul-performers-black-history-and-u-s-history-inseparable/1079183001/>Performers say black history, U.S. history are inseparable</a>
The show invited Agen to be a surprise guest judge when open-call auditions for Season 15 were staged last month at Bankers Life Fieldhouse
"It was cool being on the other side of it," she said
who will perform Saturday at Bankers Life Fieldhouse as part of the annual Winter Jam tour featuring&nbsp;contemporary Christian acts
Agen lives within a few blocks of Allen County War Memorial Coliseum
a venue that's another regular stop for Winter Jam
who sings at Come2Go Ministries in Fort Wayne
said she's attended Winter Jam concerts every year for about a decade
A special guest at Winter Jam dates in Indianapolis
Agen said she jumped at the chance to perform
"Every year it&rsquo;s been inspirational," Agen said
"It was like the easiest 'yes'&nbsp;of my life." Founded by the band NewSong in 1995
Winter Jam is a $15 ticket attendees purchase at the door
This year's headliner is rock band Skillet
After &lsquo;The Voice&rsquo;Unlike Season 13 winner Chloe Kohanski
Agen isn't signed to a major-label recording contract
After being part of "The Voice" musical factory for about half of 2017
Agen is back from the West Coast to continue her career from a base in Indiana
"It's not the name of 'The Voice' and that logo anymore," she said
"It's finding our own people to trust and work with." Committed to a singing career
Agen executes her high-school studies online
"But it&rsquo;s sure going to be an experience to remember."
Maroon manAgen speaks highly of Maroon 5 vocalist Levine
her coach during the home stretch of "The Voice" season
as someone who wants to help fellow artists
"He&rsquo;s extremely smart in business and extremely talented in music," Agen said
and he&rsquo;s wanting to share it with more people." She said her access to celebrity coaches was more than she expected
"But you actually become good friends with these people
For Agen's&nbsp;televised blind audition for "The Voice," she sang <a href="https://www.youtube.com/watch?v=k_8xgmfUEHg">Ray LaMontagne&rsquo;s &ldquo;Jolene&rdquo;</a>&nbsp;&mdash; a 2004 tune based on self-destructive behavior and lost love
"That song has been huge in my life," Agen said
"It&rsquo;s an extremely painful song in the lyrics
(Rehearsing)&nbsp;was pretty much just me figuring out more about the lyrics and how to feel it even more
coming from a 16-year-old who&rsquo;s never been through the experience he went through for that song
It was a story I wanted to bring hope to.&nbsp;It didn&rsquo;t have to turn out the way it did in the song."
>> INFO: Visit <a href=http://2018.jamtour.com/cities/indianapolis-in>2018JamTour.com</a>
Call IndyStar reporter David Lindquist at (317) 444-6404. Follow him on Twitter: <a href=https://twitter.com/317lindquist>@317Lindquist</a>.
Tadej Pogacar remains in leader&#x27;s yellow jersey
You can read our report on another Jasper Philipsen stage win <a href="https://www.bbc.co.uk/sport/cycling/articles/cg3m2yy0l88o" class="ssrcss-k8mrr8-InlineLink e1kn3p7n0">right here</a>
the Tour heads into the Pyrenees for the start of a brutal and crucial period in the general classification race
You can follow all the action with us on the 151.9km route from Pau to Saint-Lary-Soulan Pla d&#x27;Adet
144Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>GC standings after stage 13published at 16:36 British Summer Time 12 July 202416:36 BST 12 July 20241
Tadej Pogacar (Slo/UAE Team Emirates) 52hrs 40mins 58secs
Remco Evenepoel (Bel/Soudal-Quick Step) +1min 06secs
Jonas Vingegaard (Den/Visma-Lease a Bike) +1min 14secs
Joao Almeida (Por/UAE Team Emirates) +4mins 20secs
Carlos Rodriguez (Spa/Ineos Grenadiers) +4mins 40secs
Mikel Landa (Spa/Soudal-Quick Step) +5mins 38secs
Adam Yates (GB/UAE Team Emirates) +6mins 59secs
Giulio Ciccone (Ita/Lidl-Trek) +7mins 36secs
Derek Gee (Can/Israel- Premier Tech) +7mins 54secs
Felix Gall (Aut/Decathlon AG2R La Mondiale) +9mins 18secs
236Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>&#x27;My best feeling so far&#x27; at Tourpublished at 16:31 British Summer Time 12 July 202416:31 BST 12 July 2024Image source
who now has two stage wins in this edition of the Tour speaking to reporters at the finish: “It was full gas from the start
there was crosswinds and a big group ahead
&quot;We had two guys in that and I thought they would continue to the line but the peloton kept on going
But I also kept on believing because the feeling was good
much better than I had in the previous week
so I could start my sprint with confidence and I’m happy nobody could pass.”
I was a bit in the wind and had to launch early and I could pass him so I am really happy with my sprint
&quot;I had my best feeling so far in the Tour de France
I always want more but we just have to go day by day.&quot;
1615Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Stage 13 resultspublished at 16:25 British Summer Time 12 July 202416:25 BST 12 July 20241
Jasper Philipsen (Bel/Alpecin-Deceuninck) 3hrs 23mins 09 secs
Wout van Aert (Bel/Visma-Lease a Bike) Same time
Pascal Ackermann (Ger/Israel-Premier Tech) &quot;
Biniam Girmay (Eri/Intermarche-Wanty) &quot;
Nikias Arndt (Ger/Bahrain Victorious) &quot;
Tim Wellens (Bel/UAE Team Emirates) &quot;
Tadej Pogacar (Slo/UAE Team Emirates) &quot;
Soren Waerenskjold (Nor/Uno-X Mobility) &quot;
225Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>The race for the green jersey reignitespublished at 16:19 British Summer Time 12 July 202416:19 BST 12 July 2024Pascal Ackermann was third there
The race for the green jersey is suddenly back on
Girmay now leads Jasper Philipsen by 75 points
3423Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 16:15 British Summer Time 12 July 202416:15 BST 12 July 2024Cees Bol went absolutely flying in that pile up
Remco Evenepoel and Jonas Vingegaard all safely navigated away from that
4510Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Philipsen wins stage 13published at 16:12 British Summer Time 12 July 202416:12 BST 12 July 2024Image source
Getty ImagesJasper Philipsen goes...here comes Wout van Aert but he can&#x27;t catch his compatriot
3168Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 500m to go500m to goOh my there&#x27;s a huge crash down the left as Arnaud de Lie tries to force his way through..
14113Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 2km to go2km to goIntermarche-Wanty get to the front...
217Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 2.5km to go2.5km to goJonas Abrahamsen still has a small gap but that was never going to work
albeit he has stretched out the chasing group
173Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 3.2km to go3.2km to goJonas Abrahamsen attacks off the front
208Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 4km to go4km to goJasper Philipsen is sat on the wheel of Biniam Girmay
1911Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 6km to go6km to goBiniam Girmay
is loitering with intent with at least two team-mates for company
375Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 8km to go8km to goA little gap opens up at the front as Geraint Thomas relaxes and drops off the back
1116Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 11km to go11km to goMathieu Burgaudeau flies past Jasper Stuyen but a stretched chasing group is still gaining ground
93Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 12km to go12km to goMathieu Burgaudeau zips off the front of the main bunch and takes Christophe Laporte with him
72Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 15km to go15km to goJasper Stuyven and Brent van Moer ditch French rider Fabien Grellier
They will need to open a fairly hefty gap up from the 15 seconds they currently have on the main bunch
61Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 19km to go19km to goTotalEnergies rider Fabien Grellier decides to launch a counter off the front and is immediately chased and passed by Jasper Stuyven (Lidl-Trek)
Brent van Moer (Lotto-dstny) makes it a trio but this looks unlikely to stay clear
82Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 20km to go20km to goThe front of the race comes back together and Biniam Girmay is the only sprinter remaining with a decent lead-out train
262Shareclose panelShare pageCopy link<a href="https://www.bbc.co.uk/usingthebbc/terms/can-i-share-things-from-the-bbc" class="ssrcss-knigce-StyledLink ezys19s0">About sharing</a>Postpublished at 22km to go22km to goArnaud de Lie (Lotto Dstny) has got his team on the front of the peloton to increase the pace
perhaps to try and get rid of some of the sprinters as they head up an uncategorised climb
The gap to Richard Carapaz and Tobis Johannessen is around 10 seconds and falling..
Jarrod Agen celebrated his 41st birthday alone in a hotel room in Papua New Guinea
It was the final stop on a grueling November swing with Vice President Mike Pence through Japan
which made the last day of the trip feel like two
who also runs the vice president’s communications team
is perfectly content with the demands of his senior White House role
even if it requires 12-hour days at the office and nonstop weekend calls from his boss and colleagues
“It is an amazing opportunity to work in the White House,” said Agen
“If you’re not willing to put in the long days and work
there’s a million people that want to do it
In the two years since he signed on to Pence’s team
Agen has become one of the vice president’s most trusted advisers — and the vice president a constant presence in Agen’s life
Colleagues joke that one of the only times Agen has managed to escape weekend phone calls was one Sunday last month
when he was busy running in the 43rd annual Marine Corps Marathon and left his work phone at home
Agen served as chief of staff to outgoing Michigan Gov
Rick Snyder prior to relocating to Washington
where he had lived years ago during high-level stints at DHS
EPA and the State Department during the George W
His state-level experience is just as expansive: He worked for Rudy Giuliani in New York during the former mayor’s 2008 presidential bid
joined a technology startup in Silicon Valley
served on the Senate campaign of Republican Sharron Angle in Nevada and became communications director for former California GOP gubernatorial candidate Steve Poizner — all before he landed in Michigan in 2014
“The background he had was very helpful because he knew how to marry together policy and communications,” said Snyder
who still connects with Agen during visits to D.C
and offered a self-described “glowing endorsement” when his former chief of staff sought to join Pence’s team
Agen oversees communications for the vice president and assists with political strategy and policy matters
with whom he meets shortly after arriving in the office most days
“There are just a handful of people in the vice president’s world
that he relies upon and that give him a sense of comfort
and Jarrod has become one of those key people,” said Pence’s former press secretary
Main page photo courtesy of the Office of the Vice President
Story page photo by Justin Sullivan/Getty Images
Small-cap stocks could get a boost from the central bank&#x27;s anticipated rate cuts in 2025
These three stocks may be a great way to get ahead of this catalyst
Small-cap and mid-cap stocks tend to be interest rate sensitive
The core reason is that many of these companies are dependent on debt instruments to meet their long-term financial obligations
Although the Federal Reserve is wobbling on a possible rate reduction this year due to sticky inflation
the central bank is widely expected to slash rates no later than 2025
This event should prove to be a major catalyst for smaller companies that have struggled in this high-rate environment
Which small-cap growth stocks are worth building a position in ahead of this catalyst
Here is a brief overview of three stocks that could soar when interest rates fall
Agenus (<a class="ticker-symbol" href="/quote/nasdaq/agen/">AGEN</a> -0.64%) is a small-cap immunology company staring down several potent catalysts
the company has designs on a possible accelerated regulatory filing for an antibody cocktail intended as a treatment for advanced metastatic microsatellite stable colorectal cancer without active liver metastases
Agenus plans to broaden the total addressable market for its lead antibody regimen
which could transform the therapy into a multi-billion-dollar-a-year earner
but the market appears to be giving Agenus zero chance of success based on its tiny market cap of $224 million
This extreme pessimism could represent a tremendous opportunity for risk-tolerant investors
With a recent cash infusion from Ligand Pharmaceuticals
Agenus should have the cash to reach this important regulatory milestone and a parade of other clinical catalysts in 2025
regulatory hiccups or clinical setbacks should be carefully considered before buying shares
Canopy Growth (<a class="ticker-symbol" href="/quote/nasdaq/cgc/">CGC</a> -4.89%) is a Canadian licensed cannabis cultivator
Its shares have nearly doubled this year in response to the U.S.'s proposed reclassification of cannabis from Schedule 1 to Schedule 3 under the Controlled Substances Act
given that Canopy's home base is Canada and it can't yet truly benefit from positive changes in the American regulatory landscape
But the market isn't being irrational in this case
market as soon as the legal landscape permits
The bottom line is that this Canadian <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/marijuana-stocks/">cannabis stock</a> isn't a great pick for those with a short-term mindset
the company's long-term strategy could make it a formidable player in the global marijuana market before the decade's end
Curaleaf Holdings (<a class="ticker-symbol" href="/quote/otc/curlf/">CURLF</a> -2.92%) bills itself as the world's leading cannabis company
The company sports a top-tier market position in Europe and a coast-to-coast footprint in the United States
may represent a cumulative commercial opportunity of nearly $300 billion
The regulatory landscape for marijuana globally remains a mess
and it could take another decade to sort it out
but the opportunity for long-term shareholders is indeed real
Curaleaf holds generational wealth-building potential because of its frontrunner status in terms of international expansion among U.S
Morningstar analyst Kristoffer Inton noted recently that Curaleaf scans as "one of the most attractively priced cannabis stocks" because of its opportunities domestically and abroad
While analyst notes should always be taken with a grain of salt
Curaleaf does seem to have a multi-decade growth ramp ahead of it
may be worth the risk for aggressive investors
<a href="https://www.fool.com/author/7472/">George Budwell</a> has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a <a href="https://www.fool.com/legal/fool-disclosure-policy/">disclosure policy</a>
You don't have permission to access the page you requested
What is this page?The website you are visiting is protected.For security reasons this page cannot be displayed.